Nutra Pharma (OTCMKTS:NPHC) vs. Seer (NASDAQ:SEER) Head-To-Head Comparison

Nutra Pharma (OTCMKTS:NPHC) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Nutra Pharma and Seer”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutra Pharma	$390,000.00	5.51	-$1.29 million	N/A	N/A
Seer	$16.58 million	6.64	-$73.60 million	($1.28)	-1.52

Nutra Pharma has higher earnings, but lower revenue than Seer.

Analyst Recommendations

This is a summary of current ratings and target prices for Nutra Pharma and Seer, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutra Pharma	0	0	0	0	0.00
Seer	1	0	1	1	2.67

Seer has a consensus target price of $4.00, indicating a potential upside of 105.13%. Given Seer’s stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than Nutra Pharma.

Insider and Institutional Ownership

75.2% of Seer shares are held by institutional investors. 61.5% of Nutra Pharma shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Nutra Pharma has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Nutra Pharma and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutra Pharma	-429.26%	N/A	-106.42%
Seer	-443.96%	-26.04%	-23.10%

Summary

Seer beats Nutra Pharma on 9 of the 13 factors compared between the two stocks.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.